(Lung Cancer) Patritumab Deruxtecan Phase III Clinical Trial Begins
(Lung Cancer) Patritumab Deruxtecan Phase III Clinical Trial Begins
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) Patritumab Deruxtecan Phase III Clinical Trial Begins
- August 17, 2022
- 1 min read
On August 9, 2022, Daiichi Sankyo announced the initiation of patient dosing in the HERTHENA-Lung02 Phase III clinical trial evaluating Patritumab Deruxtecan as second-line treatment for EGFR-mutant metastatic non-small cell lung cancer patients.
Lung cancer is the second most common cancer worldwide. Non-small cell lung cancer accounts for 80-85% of lung cancer cases, of which approximately 30% harbor EGFR mutations. With the advent of molecular targeted drugs and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors have been established as treatment options for EGFR-mutant advanced non-small cell lung cancer. However, most patients receiving EGFR tyrosine kinase inhibitor therapy eventually develop resistance, creating a need for new treatment options.
The HERTHENA-Lung02 Phase III clinical trial will treat EGFR-mutant metastatic non-small cell lung cancer patients who have received prior EGFR tyrosine kinase inhibitor therapy with patritumab deruxtecan and evaluate its efficacy and safety. The trial is currently being conducted in Japan, Europe, North America, and Oceania, with an expected enrollment of 560 patients.
The primary efficacy endpoint is progression-free survival, and secondary endpoints include overall survival, objective response rate, clinical benefit rate, disease control rate, and duration of response.
Daiichi Sankyo stated in its press release that it will accelerate the development of this drug to provide a new treatment option for EGFR-mutant metastatic non-small cell lung cancer patients.
Source: https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202208/20220809_J.pdf
-
Investigational drug
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.